Today: 25 January 2026
Subscribe
Browse Category

NASDAQ:NBY News 10 January 2026 - 11 January 2026

NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

New York, January 10, 2026, 18:35 EST — Market closed Shares of NovaBay Pharmaceuticals Inc soared on Friday, closing up roughly 103% at $19.16. Over 10 million shares changed hands, market data showed. NovaBay is back on momentum screens before the next U.S. session, trading in a price range unseen for over a year. Why it matters now: NovaBay’s size…
11 January 2026
·····
NovaBay stock more than doubles as microcap swings widen; warrants in focus ahead of CPI

NovaBay stock more than doubles as microcap swings widen; warrants in focus ahead of CPI

New York, Jan 10, 2026, 05:29 EST — Market closed NovaBay Pharmaceuticals Inc (NBY) shares surged 102.5% on Friday, closing at $19.16 after swinging between $9.69 and $19.95 during the session. Roughly 10 million shares traded, pushing the stock to a new 52-week high. (StockAnalysis) This move is significant because such rapid shifts can draw in momentum traders—and then reverse…
10 January 2026
····

Stock Market Today

  • Selective Insurance Group (SIGI) Valuation Edges Slightly Above Market Amid Weaker Shares
    January 25, 2026, 1:42 AM EST. Selective Insurance Group (SIGI) shares have softened, down about 5% over the past month and 12% over the past year, despite the company reporting a strong annual revenue of $5.23 billion and net income of $397.5 million. The stock currently trades near $80.07, slightly below the consensus fair value estimate of $81.50. Analysts cite concerns over higher commercial auto reserve risks and slower premium growth, which have led to a downward revision of the price target to $81.50. Although SIGI shows positive revenue and earnings growth, momentum has faded recently. Investors should weigh these risks against the company's fundamentals and growth outlook when evaluating the stock's valuation.
Go toTop